Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Vxag11nn

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 1 (2)
Phase 2/3 (1)

Trial Status

Completed3
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07866469Not ApplicableActive Not Recruiting

Norovirus Prevalence and Fecal Microbiome Characterization Through Metagenomic and Metatranscriptomic Analyses

NCT03897309Phase 1CompletedPrimary

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT03721549Phase 1CompletedPrimary

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

NCT00302640Phase 2/3Completed

Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children

Showing all 4 trials

Research Network

Common Treatments

  • Vxag11nn1
  • Characterization The Fecal Microbiome Composition In Travelers1
  • Nitazoxanide1
  • Norwalk Gi1 Virus1
  • Vxag24ns1

Active Sponsors

  • Vaxart2
  • IRCCS Sacro Cuore Don Calabria di Negrar1
  • Romark Laboratories L.C.1
  • WCCT Global1

Top Investigators

Related Conditions

  • Microbiome1
  • Adenoviridae Infection1
  • Metagenomic Next Generation Sequencing1
  • Rotavirus Infection1

Activity Timeline